The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that five abstracts connected to its successful Phase 2 study NEFIGAN have been accepted by the International IgA Nephropathy Network meeting (IIgANN) in Buenos Aries, Argentina, September 27-29, 2018.The new results stem from exploratory analyses and extended post-hoc analyses of the randomized, double-blind controlled Phase 2b study NEFIGAN which Calliditas conducted with 149 IgA nephropathy (IgAN) patients at risk of developing ESRD. In 2017, the primary results from nine months’ treatment with either Nefecon or placebo